1. How informed is consent
How informed is consent? Using a continuous consent process among high-risk women who engage in transactional sex in the MDP301 vaginal microbicide trial, Mwanza, Tanzania
Andrew Vallely1,2, Shelley Lees2,3, Charles Shagi1, Stella Kasindi1, Lisa Vallely3, Selephina Soteli1, Natujwa Kavit1, Sheena McCormack4, Robert Pool5 and Richard J Hayes2 on behalf of the Microbicides Development Programme
1African Medical and Research Foundation, Mwanza, Tanzania; 2London School of Hygiene & Tropical Medicine, London, UK; 3National Institute for Medical Research, Mwanza, Tanzania; 4Medical Research Council Clinical Trials Unit, London, UK; 5Centre for International Health, University of Barcelona, Spain

2. Objectives
To understand the effectiveness of locally-appropriate procedures for obtaining informed consent in the MDP301 phase III vaginal microbicide trial in Tanzania.

3. Study population
An occupational cohort of women who work in bars, restaurants, guesthouses and other food outlets and recreational facilities in Mwanza City, northern Tanzania

4. Grocery (left) and modern bar (right), Mwanza

5. Traditional bar (kilabu), Mwanza

6. Restaurant, Mwanza

7. Feasibility Study
1573 participants enrolled and FU for up to 18 months; study ran from Jul02-Mar05
High baseline prevalances of HIV, STIs and vaginal infections (e.g. HIV 26%; HSV-2 75%; BV 53%); HIV incidence 3.5/100 PYs
Poor education levels and high rates of illiteracy observed (e.g. 24% did not complete primary education)
Ref: Vallely A et al; Sex Trans Dis 2007; [E-pub ahead of print]

8. Continuous consent
Experience during feasibility led to re-appraisal of informed consent procedures in consultation with community stakeholders
‘Continuous consent’ combines community and clinic-based components
Consent seen as a process from first contact in the community to final visit in the clinic rather than a point activity at study entry

9. Facility-based mobilisation

10. Screening & Enrolment Flipchart (groups) Information Sheet
Comprehension Checklist
Informed Consent Forms
Audio-cassette and pictorial directions on gel use (enrolment)

11. Follow-up visits
Audio cassette at any clinic visit as indicated / requested by ppt
Comprehension checklist at 12, 24, 40, 52 wk clinic visits

12. How effective is this approach?
In order to understand how well women internalize and retain key messages, in-depth interviews (IDIs) are being carried out in a random sample immediately after their 4, 24 and 52 wk follow-up visits

13. Results
To date (end-Jun07) 104 women have completed IDIs (67x4wk; 30x24wk; 7x52wk)
In all interviews there was evidence of good comprehension and retention of key messages e.g.
why is the trial being carried out?
does the gel protect against HIV?

14. Why is the trial being carried out?
All of the 104 women interviewed had at least a basic understanding of why the trial was being conducted
"They are trying the gel so that they may be sure if it will help to prevent infections of HIV/AIDS so that people could start using it.“
“When we went to the clinic they told us that there were two types of gel, there is a gel with medicine and a gel without medicine, now for us that use the gel we do not know if it has medicine or not.”

15. Does the gel protect against HIV?
81/104 (78%) said that the gel did not protect against HIV
“At present I do not know… until after the results are examined by those experts, they will know and will inform us. But I am hopeful that it [gel] can help.”

16. 23/104 (22%) were ‘unsure’ if the gel might be working, reasoning that the trial is on-going
“I can’t trust it [the gel] so much since its still on trial”
“I am not sure with gel because we haven’t reached the end of the study, we don’t know yet if it protects or not.”
“I am not sure [gel works] because it’s on trial…that’s why I use condoms."

17. Some women in both groups also commented on the gel perhaps having indirect protective effects
“I think the gel can protect against infections, maybe…it can even protect against other infections because you don’t get bruises.”
“That lubricant [gel] can protect against HIV/AIDS infection because you don’t get bruises… they say that this gel doesn’t have medicine…but that lubricant can prevent you from getting bruises.”

18. Conclusions Providing information to trial participants in a:
focussed, locally-appropriate manner;
using methods developed in consultation with the community; and
within a continuous informed-consent framework
…resulted in high levels of comprehension and message retention in this setting
This approach may represent a model for researchers conducting HIV prevention trials among other vulnerable high-risk groups

19. Acknowledgements
Our special thanks go to the women who participated in the feasibility study in Mwanza and those who are currently participating in the MDP301 trial
We would also like to acknowledge the contribution and support of the following:
Community Advisory Committee (CAC), MDP Mwanza
Stakeholders Advisory Group (SAG), MDP Mwanza
African Medical & Research Foundation (AMREF) MWAMKO clinical and community teams
National Institute for Medical Research (NIMR) Mwanza laboratory, social science, data entry, pharmacy teams